Category page
Drug discovery companies in Europe — biotech directory
Drug discovery companies sit at the front of the drug development chain — identifying biological targets, generating chemical or biological leads, optimizing them, and selecting candidates for preclinical development. Modalities span small molecules, biologics, peptides, ADCs, gene/cell therapy, RNA, and AI-driven approaches. European operators include Ryvu Therapeutics (Krakow), Captor Therapeutics (Wroclaw), Selvita's discovery arm, MorphoSys (Munich), Evotec (Hamburg), Atrandi Biosciences (Vilnius), and dozens of platform-stage biotechs across the directory.
Where does this category cluster most clearly?
Drug discovery is currently most visible through Poland (2), Lithuania (1), and Switzerland (1). Top cities: Basel, Switzerland (1), Vilnius, Lithuania (1), Warsaw, Poland (1), and Wroclaw, Poland (1). Most legible records: Biomatter, Captor Therapeutics, BioVersys, and Molecure.
Which standards and public evidence are already visible?
GLP (3). Latest review: 15 March 2026. Review cycle: March 2026.
Why this category matters
This page brings companies and infrastructure records into one practical category view so users can compare markets and cities more quickly.
Full list
Drug discovery records
4 category records currently match the active filter.
Current review cycle
Biomatter
VilniusLithuaniaDrug discovery
Vilnius computational-biology company building generative protein-design tools for enzyme engineering and biological product discovery.
- Lead
- Laurynas KarpusChief Executive Officer and Co-Founder
- Scale
- AI-enabled protein-discovery platform
Current review cycle
Captor Therapeutics
WroclawPolandDrug discovery
Wroclaw targeted-protein-degradation company building oncology and immunology programmes around molecular glues and degrader chemistry.
- Lead
- Michał WalczakChief Executive Officer and Chief Scientific Officer
- Scale
- Precision-degradation discovery platform
Current review cycle
BioVersys
BaselSwitzerlandDrug discovery
Basel anti-infectives discovery anchor focused on novel antibacterial programs against multidrug-resistant pathogens.
- Lead
- Marc GitzingerChief Executive Officer
- Scale
- Swiss anti-infectives discovery hub
Current review cycle
Molecure
WarsawPolandDrug discovery
Warsaw clinical-stage biotech platform developing first-in-class small-molecule programs across oncology and inflammatory-fibrotic disease.
- Lead
- Marcin Jan SzumowskiPresident of the Board and Chief Executive Officer
- Scale
- Clinical-stage drug discovery
FAQ
Frequently asked questions
- What does a drug discovery company do?
- Identifies biological targets (proteins, pathways), generates molecules that engage those targets (chemical or biological), optimizes lead compounds for potency, selectivity, pharmacokinetics, and safety, and selects clinical candidates. The deliverable is a candidate ready for IND-enabling studies. Discovery is upstream of clinical development and manufacturing.
- Which European countries lead in drug discovery?
- Switzerland (Roche, Novartis discovery, Idorsia, Basilea, Noema, BioVersys). Germany (BioNTech, Bayer, MorphoSys, Evotec). Poland's discovery cohort (Ryvu, Captor, OncoArendi, Selvita). Lithuania (Atrandi, CasZyme). Denmark (Genmab, Zealand Pharma). Sweden (BioArctic, Sobi). The UK ecosystem also informs European discovery via cross-border collaborations.
- What is the difference between drug discovery and a CRO?
- A drug discovery company owns its targets, leads, and pipeline candidates — it's building IP it intends to license, partner, or develop further. A CRO performs discovery work on behalf of clients without owning the IP. Some CROs offer "discovery services" (medicinal chemistry, biology) as paid work; this is different from being a discovery company in its own right.
- How are discovery companies verified in this directory?
- Every profile is hand-reviewed: leadership confirmed by primary source, physical site address sourced from official disclosures, pipeline and platform claims backed by patents, peer-reviewed publications, or filings, and a registry note explaining current discovery focus and stage.
Next step
Read the category, then move into cities and countries.
Use city pages for local concentration, country pages for market context, and the methodology page when you want to understand how records are reviewed.